Published in Clin Liver Dis on June 27, 2012
Hepatic gene expression profiles differentiate presymptomatic patients with mild versus severe nonalcoholic fatty liver disease. Hepatology (2013) 2.42
Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis. J Clin Gastroenterol (2015) 2.11
Total body weight loss of ≥ 10 % is associated with improved hepatic fibrosis in patients with nonalcoholic steatohepatitis. Dig Dis Sci (2014) 1.45
Noninvasive imaging assessment of non-alcoholic fatty liver disease: focus on liver scintigraphy. World J Gastroenterol (2015) 0.88
Choline's role in maintaining liver function: new evidence for epigenetic mechanisms. Curr Opin Clin Nutr Metab Care (2013) 0.85
Micro RNAs in the development of non-alcoholic fatty liver disease. World J Hepatol (2015) 0.79
Clinical spectrum of non-alcoholic fatty liver disease in diabetic and non-diabetic patients. BBA Clin (2014) 0.76
Effects of Omega-3 Fatty Acid in Nonalcoholic Fatty Liver Disease: A Meta-Analysis. Gastroenterol Res Pract (2016) 0.76
Noninvasive Markers of Fibrosis and Inflammation in Nonalcoholic Fatty Liver Disease. Curr Hepatol Rep (2016) 0.75
A multi-component classifier for nonalcoholic fatty liver disease (NAFLD) based on genomic, proteomic, and phenomic data domains. Sci Rep (2017) 0.75
Characterisation of liver fat in the UK Biobank cohort. PLoS One (2017) 0.75
Noninvasive markers: a double-edged sword that stratifies nonalcoholic steatohepatitis. Clin Mol Hepatol (2013) 0.75
Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology (2005) 29.57
Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology (2004) 18.86
The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology (2005) 15.74
Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol (1999) 14.07
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology (1999) 11.76
Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology (2006) 10.05
Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology (2006) 9.34
Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc (1980) 8.36
Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology (2010) 8.05
Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med (2010) 7.12
Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology (2005) 7.03
Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies. J Hepatol (1986) 6.20
Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology (1999) 5.75
Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology (2009) 4.82
The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol (2005) 4.65
Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med (2010) 4.14
The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut (2009) 4.01
The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology (1995) 3.73
Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ (2011) 3.69
A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology (2004) 3.61
Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology (2011) 3.57
Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology (2011) 3.55
Apoptosis and necrosis in the liver: a tale of two deaths? Hepatology (2006) 3.52
Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology (2011) 3.46
Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology (2010) 3.03
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology (2009) 2.92
Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol (2008) 2.87
The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology (2011) 2.86
From Mallory to Mallory-Denk bodies: what, how and why? Exp Cell Res (2007) 2.61
Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol (2008) 2.61
Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol (2006) 2.59
Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology (2011) 2.44
Metabolic syndrome in liver transplant recipients: prevalence, risk factors, and association with cardiovascular events. Liver Transpl (2011) 2.40
Toward unraveling the complexity of simple epithelial keratins in human disease. J Clin Invest (2009) 2.34
Survival after liver transplantation in the United States: a disease-specific analysis of the UNOS database. Liver Transpl (2004) 2.31
Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology (2003) 2.28
Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations. Mod Pathol (1998) 2.13
Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. Clin Gastroenterol Hepatol (2012) 2.11
Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease. Hepatology (2006) 2.04
Diagnosis of nonalcoholic fatty liver disease: invasive versus noninvasive. Semin Liver Dis (2008) 2.04
Ethnicity and nonalcoholic fatty liver disease. Hepatology (2012) 1.98
Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology (2006) 1.98
Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels. Hepatology (2009) 1.97
Fatty liver index and mortality: the Cremona study in the 15th year of follow-up. Hepatology (2011) 1.85
Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord (1998) 1.76
Ballooned hepatocytes in steatohepatitis: the value of keratin immunohistochemistry for diagnosis. J Hepatol (2008) 1.68
Outcomes of liver transplantation in patients with cirrhosis due to nonalcoholic steatohepatitis versus patients with cirrhosis due to alcoholic liver disease. Liver Transpl (2009) 1.67
Final results of a long-term, clinical follow-up in fatty liver patients. Scand J Gastroenterol (2009) 1.65
Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. J Gastroenterol Hepatol (2008) 1.49
Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease. Gut (2011) 1.46
Histologic variation of grade and stage of non-alcoholic fatty liver disease in liver biopsies. Obes Surg (2005) 1.42
Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study. Am J Gastroenterol (2010) 1.37
Pathologic features associated with fibrosis in nonalcoholic fatty liver disease. Hum Pathol (2004) 1.32
Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. J Hepatol (2004) 1.24
Prognosis of patients with a diagnosis of fatty liver--a registry-based cohort study. Hepatogastroenterology (2003) 1.24
Posttransplant metabolic syndrome: an epidemic waiting to happen. Liver Transpl (2009) 1.22
Association between nonalcoholic fatty liver disease and coronary artery calcification. Dig Dis Sci (2009) 1.19
Excellent posttransplant survival for patients with nonalcoholic steatohepatitis in the United States. Liver Transpl (2012) 1.19
Increased prevalence of cardiovascular disease in Type 2 diabetic patients with non-alcoholic fatty liver disease. Diabet Med (2006) 1.16
Hepatocellular carcinoma in non-alcoholic steatohepatitis: Growing evidence of an epidemic? Hepatol Res (2011) 1.15
The Framingham risk score and heart disease in nonalcoholic fatty liver disease. Liver Int (2012) 1.15
Gender dimorphic formation of mouse Mallory-Denk bodies and the role of xenobiotic metabolism and oxidative stress. Gastroenterology (2010) 1.14
Recurrent disease following liver transplantation for nonalcoholic steatohepatitis cirrhosis. Liver Transpl (2009) 1.10
Keratin variants are overrepresented in primary biliary cirrhosis and associate with disease severity. Hepatology (2009) 1.08
The genetic background modulates susceptibility to mouse liver Mallory-Denk body formation and liver injury. Hepatology (2008) 1.07
Outcome after liver transplantation for NASH cirrhosis. Am J Transplant (2009) 1.07
Nonalcoholic steatohepatitis--a long-term follow-up study: comparison with alcoholic hepatitis in ambulatory and hospitalized patients. Dig Dis Sci (2003) 1.03
Interobserver variation in the histopathological assessment of nonalcoholic steatohepatitis. Hepatol Res (2005) 1.02
Fibrosis heterogeneity in nonalcoholic steatohepatitis and hepatitis C virus needle core biopsy specimens. Am J Clin Pathol (2005) 0.99
Role of liver biopsy and serum markers of liver fibrosis in non-alcoholic fatty liver disease. Clin Liver Dis (2007) 0.98
Proposal for a histological scoring and grading system for non-alcoholic fatty liver disease. Liver Int (2005) 0.95
Non-invasive diagnosis of nonalcoholic fatty liver and nonalcoholic steatohepatitis. J Dig Dis (2011) 0.92
Misuse of scoring systems. Hepatology (2011) 0.91
Mallory-Denk bodies are associated with outcomes and histologic features in patients with chronic hepatitis C. Clin Gastroenterol Hepatol (2011) 0.90
Cell death and nonalcoholic steatohepatitis: where is ballooning relevant? Expert Rev Gastroenterol Hepatol (2011) 0.86
Cardiovascular disease and nonalcoholic fatty liver disease: does histologic severity matter? J Clin Gastroenterol (2012) 0.84
Influence of liver biopsy heterogeneity and diagnosis of nonalcoholic steatohepatitis in subjects undergoing gastric bypass. Obes Surg (2007) 0.83
Will the increased prevalence of nonalcoholic steatohepatitis (NASH) in the age of better hepatitis C virus therapy make NASH the deadlier disease? Hepatology (2011) 0.83
Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology (2005) 29.57
Alcoholic liver disease. Hepatology (2010) 5.04
Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology (2009) 4.82
In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology (2006) 4.60
Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology (2007) 3.58
Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med (2002) 3.49
Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology (2005) 3.44
Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology (2010) 2.86
Smoking and severity of hepatic fibrosis in nonalcoholic fatty liver disease. J Hepatol (2010) 2.42
Ascitic fluid lactoferrin for diagnosis of spontaneous bacterial peritonitis. Gastroenterology (2008) 2.23
Afternoon colonoscopies have higher failure rates than morning colonoscopies. Am J Gastroenterol (2006) 2.21
Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study. J Hepatol (2009) 2.16
Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis. J Clin Gastroenterol (2015) 2.11
Renin-angiotensin system and fibrosis in non-alcoholic fatty liver disease. Liver Int (2014) 2.05
Alcoholic liver disease. Am J Gastroenterol (2009) 2.02
Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol (2004) 1.95
Smoking and increased severity of hepatic fibrosis in primary biliary cirrhosis: A cross validated retrospective assessment. Hepatology (2006) 1.79
Plasma metabolomic profile in nonalcoholic fatty liver disease. Metabolism (2010) 1.77
The significance of metabolic syndrome in the setting of recurrent hepatitis C after liver transplantation. Liver Transpl (2008) 1.75
Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD). J Hepatol (2012) 1.70
Improving compliance with postpolypectomy surveillance guidelines: an interventional study using a continuous quality improvement initiative. Gastrointest Endosc (2006) 1.59
Progressive primary sclerosing cholangitis requiring liver transplantation is associated with reduced need for colectomy in patients with ulcerative colitis. Clin Gastroenterol Hepatol (2012) 1.56
Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology (2011) 1.47
Nonalcoholic steatohepatitis in children: a multicenter clinicopathological study. Hepatology (2009) 1.37
Pathogenesis of non-alcoholic steatohepatitis: human data. Clin Liver Dis (2007) 1.33
Pathologic features associated with fibrosis in nonalcoholic fatty liver disease. Hum Pathol (2004) 1.32
Diabetes mellitus, obesity, and hepatic steatosis. Semin Gastrointest Dis (2002) 1.27
Obesity and non-alcoholic fatty liver disease in chronic hepatitis C. J Clin Gastroenterol (2004) 1.23
Posttransplant metabolic syndrome: an epidemic waiting to happen. Liver Transpl (2009) 1.22
Role of ceramides in nonalcoholic fatty liver disease. Trends Endocrinol Metab (2012) 1.20
Measuring protein synthesis using metabolic ²H labeling, high-resolution mass spectrometry, and an algorithm. Anal Biochem (2011) 1.16
Quantification of ceramide species in biological samples by liquid chromatography electrospray ionization tandem mass spectrometry. Anal Biochem (2010) 1.15
Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: new evidence on the potential therapeutic mechanism. Hepatology (2012) 1.14
Skeletal muscle atrophy is associated with an increased expression of myostatin and impaired satellite cell function in the portacaval anastamosis rat. Am J Physiol Gastrointest Liver Physiol (2004) 1.13
Steatohepatitis in obese individuals. Best Pract Res Clin Gastroenterol (2002) 1.12
Plasma proteome dynamics: analysis of lipoproteins and acute phase response proteins with 2H2O metabolic labeling. Mol Cell Proteomics (2012) 1.05
Risk factors of non-alcoholic fatty liver disease in patients with inflammatory bowel disease. J Crohns Colitis (2012) 1.04
Gender differences in the regulation of amino acid metabolism. J Appl Physiol (1985) (2003) 1.03
Altered expression of genes regulating skeletal muscle mass in the portacaval anastomosis rat. Am J Physiol Gastrointest Liver Physiol (2006) 1.02
Reversal of sarcopenia predicts survival after a transjugular intrahepatic portosystemic stent. Eur J Gastroenterol Hepatol (2013) 1.01
Hypovitaminosis D is associated with increased whole body fat mass and greater severity of non-alcoholic fatty liver disease. Liver Int (2013) 1.00
Sarcopenia associated with portosystemic shunting is reversed by follistatin. J Hepatol (2010) 0.99
Short-term exercise reduces markers of hepatocyte apoptosis in nonalcoholic fatty liver disease. J Appl Physiol (1985) (2012) 0.96
Glycine and urea kinetics in nonalcoholic steatohepatitis in human: effect of intralipid infusion. Am J Physiol Gastrointest Liver Physiol (2009) 0.95
Prevalence of hypothyroidism in nonalcoholic fatty liver disease. Dig Dis Sci (2011) 0.94
Increased serum levels of carbohydrate antigen 19-9 and outcomes in primary sclerosing cholangitis patients without cholangiocarcinoma. Dig Dis Sci (2012) 0.92
Metabolic syndrome, non-alcoholic fatty liver disease and hepatitis C virus: impact on disease progression and treatment response. Liver Int (2009) 0.91
Predictors of steatohepatitis and advanced fibrosis in non-alcoholic fatty liver disease. Clin Liver Dis (2009) 0.90
Relations of steatosis type, grade, and zonality to histological features in pediatric nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr (2011) 0.89
Thiazolidinediones for nonalcoholic steatohepatitis--promising but not ready for prime time. N Engl J Med (2006) 0.89
Improved hepatic lipid composition following short-term exercise in nonalcoholic fatty liver disease. J Clin Endocrinol Metab (2013) 0.89
Future trends in hepatology: challenges and opportunities. Hepatology (2008) 0.89
Post-liver transplantation sarcopenia in cirrhosis: a prospective evaluation. J Gastroenterol Hepatol (2014) 0.89
Late evening snack: exploiting a period of anabolic opportunity in cirrhosis. J Gastroenterol Hepatol (2012) 0.88
Estimates of hepatic glyceroneogenesis in type 2 diabetes mellitus in humans. Metabolism (2008) 0.88
Preservation of portal pressure improves growth and metabolic profile in the male portacaval-shunted rat. Dig Dis Sci (2002) 0.88
Elevated hepatic fatty acid oxidation, high plasma fibroblast growth factor 21, and fasting bile acids in nonalcoholic steatohepatitis. Eur J Gastroenterol Hepatol (2011) 0.87
Non-alcoholic fatty liver disease and obesity: not all about body mass index. Am J Gastroenterol (2012) 0.87
Inhibition of aromatase improves nutritional status following portacaval anastomosis in male rats. J Hepatol (2006) 0.85
The impact of obesity and metabolic syndrome on alcoholic liver disease. Clin Liver Dis (2013) 0.85
Steroids or cocktails for alcoholic hepatitis. J Hepatol (2006) 0.85
Fetuin-A is linked to improved glucose tolerance after short-term exercise training in nonalcoholic fatty liver disease. J Appl Physiol (1985) (2013) 0.84
Age impacts ability of aspartate-alanine aminotransferase ratio to predict advanced fibrosis in nonalcoholic Fatty liver disease. Dig Dis Sci (2015) 0.83
Obesity and its nurturing effect on hepatitis C. Hepatology (2003) 0.81
Reduced cardiovascular risk after bariatric surgery is linked to plasma ceramides, apolipoprotein-B100, and ApoB100/A1 ratio. Surg Obes Relat Dis (2011) 0.81
Differences in regulation of type I collagen synthesis in primary and passaged hepatic stellate cell cultures: the role of alpha5beta1-integrin. Am J Physiol Gastrointest Liver Physiol (2007) 0.81
Treatment of alcoholic hepatitis. Clin Liver Dis (2005) 0.78
An improved measurement of isotopic ratios by high resolution mass spectrometry. J Am Soc Mass Spectrom (2013) 0.78
Management and outcome in hepatorenal syndrome: need for renal replacement therapy in non-transplanted patients. Int Urol Nephrol (2013) 0.77
Obesity, hepatic metabolism and disease. Nestle Nutr Workshop Ser Pediatr Program (2009) 0.77
Association between fatigue and decreased survival in primary biliary cirrhosis. Gut (2007) 0.75
Proteome Dynamics Reveals Pro-Inflammatory Remodeling of Plasma Proteome in a Mouse Model of NAFLD. J Proteome Res (2016) 0.75
Impact of budesonide on liver function tests and gut inflammation in patients with primary sclerosing cholangitis and ileal pouch anal anastomosis. J Crohns Colitis (2011) 0.75
Beneficial effect of midodrine in hypotensive cirrhotic patients with refractory ascites. Gastroenterol Hepatol (N Y) (2011) 0.75
How good is transjugular liver biopsy for the histological evaluation of liver disease? Nat Clin Pract Gastroenterol Hepatol (2007) 0.75
In Response. J Clin Gastroenterol (2016) 0.75
High prevalence of normal serum albumin in NASH patients with ascites: a retrospective analysis. Clin Res Hepatol Gastroenterol (2012) 0.75
Impact of De Novo and Preexisting Inflammatory Bowel Disease on the Outcome of Orthotopic Liver Transplantation. Inflamm Bowel Dis (2016) 0.75
Nonalcoholic steatohepatitis recurrence and rate of fibrosis progression following liver transplantation. Eur J Gastroenterol Hepatol (2017) 0.75
Stage of fibrosis and portal pressure correlation in nonalcoholic steatohepatitis. Eur J Gastroenterol Hepatol (2017) 0.75
The association of nonalcoholic steatohepatitis and obstructive sleep apnea. Eur J Gastroenterol Hepatol (2017) 0.75
The TMAO-Producing Enzyme Flavin-Containing Monooxygenase 3 Regulates Obesity and the Beiging of White Adipose Tissue. Cell Rep (2017) 0.75